DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 224-229

  von Pawel, Joachim ^a   Gorbounova, Vera ^b   Reck, Martin ^c   Kowalski, Dariusz M ^d   Allard, Aurore ^e   Chadjaa, Mustapha ^e   Rey, Augustin ^e   Bennouna, Jaafar ^f   Grossi, Francesco ^g  

^a Asklepios Fachkliniken   (Germany)

^b Cancer Research Center   (Russian Federation)

^c GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e SANOFI   (France)

^f UMR INSERM U892 CNRS 6299   (France)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Non small cell lung cancer (NSCLC); Ombrabulin; Phase 2; Platinum; Taxane

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; OMBRABULIN; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; PLATINUM; SERINE; TAXANE; TAXOID;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LIMB PAIN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PLATINUM; SERINE; TAXOIDS; TREATMENT OUTCOME;

EID: 84904102075     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.05.013     Document Type: Article

References (21)

1. Janku F., Stewart D.J., Kurzrock R. Targeted therapy in non-small-cell lung cancer - is it becoming a reality?. Nat Rev Clin Oncol 2010, 7:401-414.
2. Schiller J.H., Harrington D., Belani C.P. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Grossi F., Kubota K., Cappuzzo F., de Marinis F., Gridelli C., Aita M., et al. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist 2010, 15:1102-1112.
4. Ma P.C. Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 2012, 79:eS56-eS60.
5. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
6. Zhou C., Wu Y.L., Chen G., Feng J.F., Liu X., Wang C., et al. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl. 15):7520.
7. Sequist L., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
8. Sandler A., Gray R., Perry M.C. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
9. Genova C., Rijavec E., Truini A., Coco S., Sini C., Barletta G., et al. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013, 14:1545-1558.
10. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997, 15:1829-1834.
11. Blakey D.C., Westwood F.R., Walker M., Hughes G.D., Davis P.D., Ashton S.E., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002, 8:1974-1983.
12. Hori K., Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumor blood flow stasis. Br J Cancer 2003, 6:1334-1344.
13. Siemann D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 2011, 37:63-74.
14. Hori K., Saito S., Nihei Y., Suzuki M., Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999, 90:1026-1038.
15. Kim T.J., Ravoori M., Landen C.N., Kamat A.A., Han L.Y., Lu C., et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007, 67:9337-9345.
16. Morinaga Y., Suga Y., Ehara S., Harada K., Nihei Y., Suzuki M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 2003, 94:200-204.
17. Demers B., Vrignaud P., Bissery M. In vivo synergy combining oxaliplatin with AVE8062, a vascular-disrupting agent. J Clin Oncol 2006, 24(Suppl. 18):13074.
18. Soria J.C., Bahleda R., Besse B., Sessa C., Calderone R., Gianni L., et al. Phase I study of the vascular disrupting agent (VDA) ombrabulin (Ob) in combination with taxanes (T) and platinum salts (PS) in patients (pts) with advanced solid tumors. Eur J Cancer (EORTC-NCI-AACR) 2010, (Suppl. 8):122-123. 386.
19. Lara P.N., Douillard J.Y., Nakagawa K., von Pawel J., McKeage M.J., Albert I., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:2965-2971.
20. Lorusso P.M., Boerner S.A., Hunsberger S. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?. J Clin Oncol 2011, 29:2952-2955.
21. Garon E.B., Kabbinavar F.F., Neidhart J.A., Neidhart J.D., Gabrail N.Y., Oliveira M.R., et al. A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial. J Clin Oncol 2011, 29(Suppl. 15):7559.